This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MLND Millendo Therapeutics (MLND) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Millendo Therapeutics Stock (NASDAQ:MLND) Get Millendo Therapeutics alerts:Sign Up Key Stats Today's Range$1.54▼$1.6150-Day Range$3.06▼$5.8452-Week Range$0.92▼$16.95Volume152,321 shsAverage Volume1.52 million shsMarket Capitalization$29.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan. Read More Receive MLND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLND Stock News HeadlinesRelease Therapeutics Secures CHF 3.3 Million in Seed FundingAugust 6, 2024 | tmcnet.comA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessMarch 20, 2024 | msn.comThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment demand for gold rose 84 percent last year, according to Kitco, and Rickards projects prices could climb toward 10,000 dollars within 12 months. Rickards has identified a 2 dollar gold stock tied to a September 30 catalyst that he believes is positioned for major gains as this trend accelerates.September 20 at 1:00 AM | Paradigm Press (Ad)Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementJanuary 11, 2024 | markets.businessinsider.comWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?December 5, 2023 | msn.comMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)November 6, 2023 | markets.businessinsider.comExpert Ratings for Decibel TherapeuticsMarch 15, 2023 | benzinga.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call TranscriptDecember 29, 2022 | insidermonkey.comSee More Headlines MLND Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Millendo Therapeutics investors own include Elbit Systems (ESLT), UnitedHealth Group (UNH), AbbVie (ABBV), American Water Works (AWK), Bright Health Group (BHG), Black Hills (BKH) and Blackrock Municipal 2030 Target Term Trust (BTT). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MLND CIKN/A Webwww.millendo.com Phone734 845 9000FaxN/AEmployees12Year Founded2012Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-91.03% Return on Assets-72.44% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.88Miscellaneous Outstanding Shares19,043,000Free FloatN/AMarket Cap$29.71 million OptionableNot Optionable Beta0.48 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MLND) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredWhat Elon Musk did in June 2024In June 2024, Elon Musk faced a problem every AI company was about to hit — how to power a massive AI computer...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
